Loss and reduced expression of PTEN correlate with advanced-stage gastric carcinoma

Experimental and Therapeutic Medicine

Volumn 5, Issue 1, 2013, Pages 57-64

  Zhu, Xuehua ^a   Qin, Xia ^b   Fei, Maogui ^c   Hou, Wenmin ^c   Greshock, Joel ^b   Bachman, Kurtis E ^b   Kang, Jiuhong ^a   Qin, Crystal Ying ^b  

^a TONGJI UNIVERSITY   (China)

^b GLAXOSMITHKLINE   (United States)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Advanced gastric carcinoma; Immunohistochemistry; Phosphatase and tensin homolog; Receiver operator characteristic curve; Tissue microarray

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STOMACH CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY;

EID: 84869412548     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.749     Document Type: Article

References (28)

1. Roder DM: The epidemiology of gastric cancer. Gastric Cancer 5: 5-11, 2002.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
4. Li DM and Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124-2129, 1997.
5. Steck PA, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997.
6. Maehama T and Dixon JE: The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phospha-tidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998.
7. Goberdhan DC and Wilson C: PTEN: tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet 12: R239-R248, 2003.
8. Stambolic V, Suzuki A, de la Pompa JL, et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998.
9. Besson A, Robbins SM and Yong VW: PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 263: 605-611, 1999.
10. Waite KA and Eng C: Protean PTEN: form and function. Am J Hum Genet 70: 829-844, 2002.
11. Kang YH, Lee HS and Kim WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82: 285-291, 2002.
12. Remmele W and Stegner HE: Recommendation for uniform defnition of an immunoreactive score (IRS) for immunohisto-chemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987 (In German).
13. Bignell GR, Greenman CD, Davies H, et al: Signatures of mutation and selection in the cancer genome. Nature 463: 893-898, 2010.
14. Salmena L, Carracedo A and Pandolf PP: Tenets of PTEN tumor suppression. Cell 133: 403-414, 2008.
15. Carracedo A, Alimonti A and Pandolf PP: PTEN level in tumor suppression: how much is too little? Cancer Res 71: 629-633, 2011.
16. Hollander MC, Blumenthal GM and Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11: 289-301, 2011.
17. Backman SA, Ghazarian D, So K, et al: Early onset of neoplasia in the prostate and skin of mice with tissue-specifc deletion of Pten. Proc Natl Acad Sci USA 101: 1725-1730, 2004.
18. Lee JI, Soria JC, Hassan KA, et al: Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127: 1441-1445, 2001.
19. Tachibana M, Shibakita M, Ohno S, et al: Expression and prognostic signifcance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94: 1955-1960, 2002.
20. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M and Sellers WR: Loss of PTEN expression in paraffn-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291-4296, 1999.
21. Depowski PL, Rosenthal SI and Ross JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 14: 672-676, 2001.
22. Sano T, Lin H, Chen X, et al: Differential expression of MMAC/ PTEN in glioblastoma multiforme: relationship to locali zation and prognosis. Cancer Res 59: 1820-1824, 1999.
23. Zheng H, Takahashi H, Murai Y, et al: Low expression of FHIT and PTEN correlates with malignancy of gastric carcinomas: tissue-array findings. Appl Immunohistochem Mol Morphol 15: 432-440, 2007.
24. Leslie NR and Foti M: Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol Sci 32: 131-140, 2011.
25. Harima Y, Sawada S, Nagata K, Sougawa M, Ostapenko V and Ohnishi T: Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol 18: 493-497, 2001.
26. Yoshimoto M, Cunha IW, Coudry RA, et al: FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97: 678-685, 2007.
27. Deng H, Wu RL, Zhou HY, Huang X, Chen Y and Liu LJ: Significance of Survivin and PTEN expression in full lymph node-examined gastric cancer. World J Gastroenterol 12: 1013-1017, 2006.
28. Bai Z, Ye Y, Chen D, et al: Homeoprotein Cdx2 and nuclear PTEN expression profles are related to gastric cancer prognosis. APMIS 115: 1383-1390, 2007.